ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways

ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways

ObjectiveSuppression of bromodomain and extra terminal (BET) proteins has a bright prospect to treat MYC-driven tumors. Bromodomain containing 4 (BRD4) is one of the BET proteins. ARV-825, consisting of a BRD4 inhibitor conjugated with a cereblon ligand using proteolysis-targeting chimera (PROTAC) t...

Full description

Bibliographic Details
Main Authors: Xinmei Liao, Xiaoqing Qian, Zimu Zhang, Yanfang Tao, Zhiheng Li, Qian Zhang, Hui Liang, Xiaolu Li, Yi Xie, Ran Zhuo, Yanling Chen, You Jiang, Haibo Cao, Jiaqi Niu, Cuili Xue, Jian Ni, Jian Pan, Daxiang Cui
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
ARV-825
BRD4
gastric cancer
c-Myc
PLK1
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.753119/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.753119/full

Similar Items